{"id":"levofloxacin-intravenous-solution","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Nausea"},{"rate":"1-3%","effect":"Diarrhea"},{"rate":"1%","effect":"Vomiting"},{"rate":"1-3%","effect":"Headache"},{"rate":"1%","effect":"Dizziness"},{"rate":"<1%","effect":"Tendinitis/tendon rupture"},{"rate":"<1%","effect":"QT prolongation"},{"rate":"<1%","effect":"Photosensitivity"},{"rate":"<1%","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone antibiotic, levofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This leads to disruption of bacterial DNA synthesis, cell death, and bactericidal activity against a broad spectrum of gram-positive and gram-negative organisms.","oneSentence":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:01.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute bacterial exacerbation of chronic bronchitis"},{"name":"Complicated urinary tract infections"},{"name":"Uncomplicated urinary tract infections"},{"name":"Acute pyelonephritis"},{"name":"Skin and soft tissue infections"},{"name":"Intra-abdominal infections"},{"name":"Bacterial prostatitis"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06049758","phase":"NA","title":"D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","status":"NOT_YET_RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2024-01-02","conditions":"Blood Loss, Intensive Care, Anastomotic Leakage","enrollment":80},{"nctId":"NCT03551210","phase":"PHASE3","title":"Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-05-04","conditions":"Pneumonia, Bacterial","enrollment":342},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT03832465","phase":"PHASE4","title":"Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-06-14","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT03234296","phase":"NA","title":"Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis","status":"ENROLLING_BY_INVITATION","sponsor":"Turku University Hospital","startDate":"2017-08-09","conditions":"Acute Appendicitis","enrollment":147},{"nctId":"NCT04456712","phase":"PHASE4","title":"Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2018-06-01","conditions":"QTc Prolongation, Hyperglycemia, Hypoglycemia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cravit intravenous solution"],"phase":"marketed","status":"active","brandName":"Levofloxacin intravenous solution","genericName":"Levofloxacin intravenous solution","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}